CAR-Ts can cure some blood cancers but are difficult to produce. A new study by Interius Biotherapeutics will test if a simple infusion could make it available for all. https://trib.al/oFSk0Fv
STAT’s Post
More Relevant Posts
-
Did you know #MRgRT is allowing #radonc clinicians to explore the use of MR biomarkers for dose escalation and improving outcomes for previously considered ‘hard-to-treat’ cancers? Hear how MR-Linacs are enabling clinicians to treat with more certainty⬇️
#MRgRT highlights from Astro23
elekta.smh.re
-
Did you know #MRgRT is allowing #radonc clinicians to explore the use of MR biomarkers for dose escalation and improving outcomes for previously considered ‘hard-to-treat’ cancers? Hear how MR-Linacs are enabling clinicians to treat with more certainty⬇️
#MRgRT highlights from Astro23
elekta.smh.re
-
Did you know #MRgRT is allowing #radonc clinicians to explore the use of MR biomarkers for dose escalation and improving outcomes for previously considered ‘hard-to-treat’ cancers? Hear how MR-Linacs are enabling clinicians to treat with more certainty⬇️
#MRgRT highlights from Astro23
elekta.smh.re
-
Did you know #MRgRT is allowing #radonc clinicians to explore the use of MR biomarkers for dose escalation and improving outcomes for previously considered ‘hard-to-treat’ cancers? Hear how MR-Linacs are enabling clinicians to treat with more certainty⬇️
#MRgRT highlights from Astro23
elekta.smh.re
-
Did you know #MRgRT is allowing #radonc clinicians to explore the use of MR biomarkers for dose escalation and improving outcomes for previously considered ‘hard-to-treat’ cancers? Hear how MR-Linacs are enabling clinicians to treat with more certainty⬇️
#MRgRT highlights from Astro23
elekta.smh.re
-
Did you know #MRgRT is allowing #radonc clinicians to explore the use of MR biomarkers for dose escalation and improving outcomes for previously considered ‘hard-to-treat’ cancers? Hear how MR-Linacs are enabling clinicians to treat with more certainty⬇️
#MRgRT highlights from Astro23
elekta.smh.re
-
Did you know #MRgRT is allowing #radonc clinicians to explore the use of MR biomarkers for dose escalation and improving outcomes for previously considered ‘hard-to-treat’ cancers? Hear how MR-Linacs are enabling clinicians to treat with more certainty⬇️
#MRgRT highlights from Astro23
elekta.smh.re
-
Did you know #MRgRT is allowing #radonc clinicians to explore the use of MR biomarkers for dose escalation and improving outcomes for previously considered ‘hard-to-treat’ cancers? Hear how MR-Linacs are enabling clinicians to treat with more certainty⬇️
#MRgRT highlights from Astro23
elekta.smh.re
-
Did you know #MRgRT is allowing #radonc clinicians to explore the use of MR biomarkers for dose escalation and improving outcomes for previously considered ‘hard-to-treat’ cancers? Hear how MR-Linacs are enabling clinicians to treat with more certainty⬇️
#MRgRT highlights from Astro23
elekta.smh.re
-
Did you know #MRgRT is allowing #radonc clinicians to explore the use of MR biomarkers for dose escalation and improving outcomes for previously considered ‘hard-to-treat’ cancers? Hear how MR-Linacs are enabling clinicians to treat with more certainty⬇️
#MRgRT highlights from Astro23
elekta.smh.re
We aim to transform the operating models underpinning the structures of biotechnology organizations
2wGreat to see the progress with in-vivo CARs. Best of luck!